Back

Impact of mandatory cardiovascular risk assessment on risk factor control and prescribing patterns in a tertiary cardiovascular centre

30 August 2026 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Prediction and prognosis of coronary artery disease (2) Cardiovascular Risk Assessment ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Miss Anastasija Palikuca

Novi Sad (Serbia)

4 More presentations in this session

Presentation thumbnail
Comparison of Cox proportional hazards models and random survival forests for long-term cardiovascular risk prediction incorporating coronary artery calcium score
Doctor G. Bettencourt Abreu (Funchal, PT)
Abstract Slides Video
Presentation thumbnail
Circadian syndrome is inversely associated with lung function and cardiorespiratory fitness in the general population
Miss N. Schmidt (Greifswald, DE)
Abstract Slides Video
Presentation thumbnail
From benign to prognostic: ectopy burden predicts long-term cardiovascular events
Doctor A. Moses (Ramat Gan, IL)
Abstract Slides Video
Presentation thumbnail
Prognostic significance of the hemoglobin–albumin–lymphocyte–platelet (HALP) score in rheumatic mitral stenosis: a long-term cohort study
Doctor K. Ahmet Ferhat (Van, TR)
Abstract Slides Video

Access the full session

Session thumbnail
Prediction and prognosis of coronary artery disease (2)

The Event

Event poster

ESC Congress 2026

30 August 2026 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Cardiovascular risk factor control after implementation of mandatory risk assessment in a tertiary cardiovascular centre
31 August 2026
thumbnail
Congress Presentation
Living longer with multiple cardiovascular conditions : challenges & solutions
4 April 2025
thumbnail
Congress Presentation
Normal coronary computed tomography angiography and long-term cardiovascular risk: implications for SCORE2–guided primary prevention
28 August 2026
thumbnail
Congress Presentation
Predicted change in 10-year cardiovascular risk one year after initiation of bempedoic acid-based therapy in the MILOS study
31 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources